Ovid Therapeutics Inc. Net Income Loss

• Ovid Therapeutics Inc. showed an increase of +34.1% in Net Income Loss from 2024 to 2025.
• This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$3.68 million | Q2 2016: -$5.39 million | Q3 2016: -$5.79 million | Q4 2016: -$7.56 million | Q1 2017: -$34.24 million | Q2 2017: -$10.25 million | Q3 2017: -$9.36 million | Q4 2017: -$10.96 million | Q1 2018: -$13.18 million | Q2 2018: -$12.94 million | Q3 2018: -$12.96 million | Q4 2018: -$12.90 million | Q1 2019: -$13.80 million | Q2 2019: -$13.06 million | Q3 2019: -$16.63 million | Q4 2019: -$16.97 million | Q1 2020: -$20.03 million | Q2 2020: -$22.55 million | Q3 2020: -$16.42 million | Q1 2021: $176.01 million | Q2 2021: -$15.79 million | Q3 2021: -$11.38 million | Q1 2022: -$16.11 million | Q2 2022: -$14.59 million | Q3 2022: -$11.97 million | Q1 2023: -$13.36 million | Q2 2023: -$12.41 million | Q3 2023: -$11.25 million | Q1 2024: -$11.69 million | Q2 2024: $8.52 million | Q3 2024: -$14.01 million | Q1 2025: -$10.24 million | Q2 2025: -$4.68 million | Q3 2025: -$12.16 million.
• Over the full 11 years of available data (2015 to 2025), Ovid Therapeutics Inc.'s Net Income Loss has declined by 32.3%.
• Historical annual values: Fiscal year 2025: -$17.41 million | Fiscal year 2024: -$26.43 million | Fiscal year 2023: -$52.34 million | Fiscal year 2022: -$54.17 million | Fiscal year 2021: $122.83 million | Fiscal year 2020: -$81.04 million | Fiscal year 2019: -$60.46 million | Fiscal year 2018: -$51.98 million | Fiscal year 2017: -$64.81 million | Fiscal year 2016: -$22.41 million | Fiscal year 2015: -$13.16 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026